Eli Lilly and Company has announced plans to invest $6.5bn in an active pharmaceutical ingredients (API) manufacturing facility at Generation Park in Houston, in the US state of Texas. The new ...

Reshoring generic pharmaceutical production is essential in today’s era of geopolitical instability and heightened awareness surrounding national health security. And it is possible—if done right.

AbbVie started construction of its new active pharmaceutical ingredient (API) manufacturing plant in North Chicago, Illinois.

Eli Lilly and Company (Lilly) plans to construct an active pharmaceutical ingredient (API) manufacturing facility, totaling around 1 million square feet, in Harris County, Texas. According to news ...

AbbVie (ABBV) announced the start of construction of its new active pharmaceutical ingredient manufacturing plant in North Chicago, Illinois. This ...

Another multi-billion-dollar company is expanding operations in Texas after receiving millions of dollars through a new taxpayer funded grant that allows for a freeze on school district property tax ...

The Houston facility has been selected as one that will make orforglipron, Lilly's new oral GLP-1 agonist for weight-loss, which is due to be filed for FDA approval before the end of the year, along ...

The API facility, which will make orforglipron amongst other small molecules, is part of Eli Lilly’s $27bn US manufacturing drive.

This review of the nitrosamines contamination problem in pharmaceuticals takes a look at how the crisis started and developed.